Look for Post-MI Patients Who May Benefit From an Aldosterone Antagonist

December 2017

You'll hear more buzz about starting an aldosterone antagonist (spironolactone, eplerenone) in eligible post-MI patients.

This isn't new information. We know adding an aldosterone antagonist to post-MI patients with "systolic" heart failure...or HFrEF...reduces mortality. But less than 20% of patients are started on one.

Help close the gap.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

New Drugs Save Meropenem/Vaborbactam for Carbapenem-Resistant Enterobacteriaceae
Dosing Don't Use Creatinine Clearance to Renally Dose All Meds
Hematology Oncology Consider a Fixed Dose of Rasburicase for Tumor Lysis Syndrome
Cardiology Look for Post-MI Patients Who May Benefit From an Aldosterone Antagonist
New Drugs Watch for Confusion Between Fiasp and NovoLog
Gastroenterology Know How to Manage Antithrombotics Around Emergent Colonoscopies
New Drugs Emphasize an Effective Bowel Regimen for Opioid-Induced Constipation
COPD Ensure Patients With Mild COPD Are on the Most Cost-Effective Regimen
New Drugs Consider Endari for Patients on Hydroxyurea Who Still Have Sickle Cell Crises
Infectious Diseases Check if Your Hospital Uses Rapid Diagnostic Tests for Acute Infectious Diarrhea
Vaccines Help Patients Understand Differences Between Zostavax and Shingrix

Look for Post-MI Patients Who May Benefit From an Aldosterone Antagonist

Get unlimited access through an Enterprise license

Table of Contents